

MATERIAL SUPPLEMENTARY

Table. Characteristics of patients

#	Age	Sex	Comorbidities	Months from SM to COVID-19	SM	SM treatment before COVID-19	Days from vaccination to COVID-19	Stay during COVID-19	COVID-19 severity	COVID-19 treatment	Follow up since COVID-19
1	65	F	-	72	Indolent	Midostaurin	None	Hospital: 36 days	Severe infection	NIV, lopinavir/ritonavir, steroids	185
2	50	F	-	60	Indolent	None	None	Home	Mild infection	None	32
3	43	F	-	11	Indolent	None	None	Home	Asymptomatic	None	320
4	24	M	-	252	Indolent	None	None	Home	Mild infection	None	259
5	60	F	Cardiopathy, CPD, DM	168	Indolent	Antihistamines	1x BioNTech/Pfizer (14)	Home	Mild infection	None	131
6	49	M	Smoking history	60	Indolent	None	2xBioNTech/Pfizer (123)	Home	Mild infection	Monocolonal antibodies	98
7	55	F	-	120	Indolent	None	None	Home	Mild infection	Steroids	386
8	63	M	-	92	Indolent	None	None	Home	Mild infection	Steroids	681
9	57	F	-	66	Indolent	Antihistamines	2x BioNTech/Pfizer (187)	Home	Asymptomatic	None	52
10	52	M	Smoking history	22	Indolent	None	None	Home	Mild infection	None	30
11	72	M	Hypothyroidism	2	Indolent	None	2xBioNTech/Pfizer (182)	Home	Asymptomatic	None	30
12	68	M	cardiopathy, smoking, aspergillosis	22	SM-AHN (CMML)	Midostaurin, conditioning for alloHSCT,	1x BioNTech/Pfizer (11)	Hospital: 19 days	Critical infection	Steroids, inotropic support, IOT, dialysis, voriconazole prophylaxis	18 (Death)
13	60	M	-	67	SM-AHN (JAK2+ ET)	Hydroxyurea	None	Hospital: 9 days	Severe infection	HCQ, lopinavir/ritonavir, O ₂ therapy	278
14	78	M	Renal impairment, smoking history	12	SM-AHN (MCL)	Chromolyn sodium, steroids, antihistamines	None	Hospital: 6 days	Severe infection	O ₂ therapy, steroids	210
15	64	M	Smoking history	7	SM-AHN (MM)	Radiation therapy	None	Home	Asymptomatic	None	267
16	52	M	Cardiopathy	60	SM-AHN (sMM)	Midostaurin	2xBioNTech/Pfizer (11)	Home	Mild infection	Steroids	139
17	67	M	-	80	Aggressive	Midostaurin, steroids	None	Home	Asymptomatic	None	84
18	46	F	Hodgking lymphoma	54	Aggressive	Midostaurin, Cladribin	None	Home	Mild infection	None	60
19	51	F	-	126	Aggressive	Midostaurin	2xBioNTech/Pfizer (126)	Home	Mild infection	Sotrovimab	30
20	63	F	Smoking history	7	AML associated	3 days of daunoblastine and 7 days of cytarabine, Midostaurin, conditioning for alloHSCT, Ruxolitinib	1x AstraZeneca (300)	Hospital: 49 days	Asymptomatic	Remdesivir	49

AHN, associated hematologic neoplasm; alloHSCT, allogenic hematopoietic stem cell transplantation; CMML, chronic myelomonocytic leukemia; COVID-19, coronavirus disease 2019; CPD, chronic pulmonary disease;; DM, diabetes mellitus; ET, essential thrombocythemia; F, female; HCQ, hydroxychloroquine; JAK2, Janus kinase 2; LPV/r, lopinavir/ritonavir; M, male; MCL, mantle cell lymphoma; MM, multiple myeloma; NIV, non invasive ventilation; O₂, oxygen; OTI, Orotracheal intubation; SM, systemic mastocytosis; sMM, smoldering myeloma